Gamma-Aminobutyric Acid (GABA) Receptor Market is segmented By Medications(Benzodiazepines, Barbiturates, Vigabatrin, Propofol, Flumazenil, Baclofen, Gabapentin, Zolpidem, Others), By Type (GABAA, GABAB), By Application (Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Psychiatric Disorders, General anesthesia, Neuropathic pain, Muscle relaxant, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis, 2023-2030
Gamma-Aminobutyric Acid (GABA) Receptor Market expected to reach at a CAGR of 4.5% during the forecast period (2023-2030).
Gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter found in the central nervous system of mammals. The neurotransmitter reduces the activity of neurons to which it binds, thus is used to control anxiety or fear when neurons are overexcited. GABA receptors are protein molecules that respond to neurotransmitter GABA.
Gamma-Aminobutyric Acid (GABA) Receptor Market
| Metrics | Details |
| Market CAGR | 4.5% |
| Segments Covered | By Medications, By Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Gamma-Aminobutyric Acid (GABA) Receptor Market Dynamics
The global gamma-aminobutyric acid (GABA) receptor market growth is driven by the rise in incidences of neurological disorders and increase in the aging population; increased funding by government and private organizations across emerging economies for the treatment of neurological disorders is expected to provide growth opportunities for market growth.
The rise in incidences of neurological disorders coupled with the introduction of novel drugs is expected to drive market growth.
The increasing prevalence of epilepsy is the major driving factor of the market. For instance, According to World Health Organization (WHO), around 50 million people worldwide have epilepsy. The average incidence of epilepsy each year in the U. S is estimated at 150,000 or 48 for every 100,000 people. Also found that in the United States, the number of males and females with epilepsy was 1,477,323 and 1,331,276, respectively, in 2017. Benzodiazepines (BZDs) are essential agents in the management of epilepsy. They are the first choice of drugs for status epilepticus and seizures associated with post-anoxic insult. They are also frequently used to treat febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include they bind to the GABA-A receptor, increasing the calming effect, rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in various clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. For instance, In January 2020, the US FDA approved Neurelis, Inc drug Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in people with epilepsy six years of age and older.
Side effects associated with the GABA receptor binding drugs are likely to hamper market growth.
The most common side effects of GABA include dizziness, anxiety, drowsiness, dry mouth, balance problems, constipation, blurred vision, itchiness, irritation, stomach pain, memory problems, increased appetite, joint and muscle pain.
Gamma-Aminobutyric Acid (GABA) Receptor Market- Industry Analysis
COVID-19 Impact Analysis
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared the COVID-19 pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics had eventual drug-drug interactions, which had a short-term negative impact on the market.
Gamma-Aminobutyric Acid (GABA) Receptor Market Segment Analysis
The diazepam segment is expected to hold the largest share in this market segment.
Diazepam is likely to be the largest segment during the forecast period due to the new route of administration, strategic collaboration between companies for the development & commercialization of diazepam, and lower prescription cost for major diazepam factors attributed to the higher growth of the diazepam segment.
For instance, Valtoco a Neurelis, Inc product is a proprietary formulation of diazepam incorporating the unique combination of a vitamin E-based solution and Intravail absorption enhancement to obtain outstanding absorption, tolerability, and reliability in a nasal formulation and; it is delivered via a nasal formulation in a spray, being developed to manage children and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. The exact mechanism of action for diazepam is not fully understood. Still, it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.
Gamma-Aminobutyric Acid (GABA) Receptor Market Geographical Analysis
North America region holds the largest market share of the global gamma-aminobutyric acid (GABA) receptor market.
North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals in that region. For instance, In February 2020, the United States Food and Drug Administration supported Merck for its Belsomra drug in treating insomnia in patients with mild-to-moderate Alzheimer's disease. An article published by the National Center for Biotechnology Information, U.S. Library of Medicine in February 2018 stated that 50,000 to 150,000 people in the U.S. suffer from status epilepticus, with mortality estimated at less than 3% in children, but up to 30% in adults. For instance, Aquestive Therapeutics collaborated with Syneos Health, Covance, in 2020 completed Phase 3 trial of safety and tolerability study of chronic intermittent use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects with Epilepsy. An increase in the development of mental healthcare services and rising awareness towards anxiety disorders are responsible for the rise in the diagnosis of a generalized anxiety disorder (GAD).
Gamma-Aminobutyric Acid (GABA) Receptor Market Competitive Landscape
Gamma-Aminobutyric acid (GABA) receptor market is highly competitive with the presence of local as well as international companies. The key players contributing to the market's growth include Merck Kagan, Bausch Health US LLC, Pfizer Inc, Lundbeck, Sanofi-Aventis U.S. LLC, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd, LGM PHARMA.
Global Gamma-Aminobutyric Acid (GABA) Receptor Market – Key Companies to Watch
Pfizer Inc
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also consists of a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: XANAX (ALPRAZOLAM)- XANAX is a benzodiazepine indicated for the acute treatment of generalized anxiety disorder in adults.
Frequently Asked Questions
What is the Projected CAGR value of the Gamma-Aminobutyric Acid (GABA) Receptor Market?
Gamma-Aminobutyric Acid (GABA) Receptor Market is expected to grow at a CAGR of 4.5% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Gamma-Aminobutyric Acid (GABA) Receptor Market during 2022-2029
Which is the fastest growing region in the Gamma-Aminobutyric Acid (GABA) Receptor Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period